NCT05198843 2025-10-03
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
National Cancer Institute (NCI)
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT01306942 2023-03-30
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT00566618 2022-02-25
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00820170 2019-08-13
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00903006 2015-02-02
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00924352 2014-10-13
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Phase 1/2 Completed